Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2020-02-01
2023-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
3.2 Investigational product and indication.
The SmartCardia patch (SmartCardia, EPFL (Ecole polytechnique fédérale Lausanne) Innovation Park, Lausanne, Switzerland) is a lightweight wireless ECG device (Figure 1) mounted on a patch with waterproof properties. The device is completely wireless and has no external connection wires. It allows patients to go about their daily activities with minimal disruption. The SmartCardia system allows in hospital patients monitoring, and corresponds to telemetry, functioning as 24 hour cardiac monitoring. The device is placed on the upper left part of the patient's chest (Figure 2). The patch can wirelessly communicate the data to a screen that will display it live. In addition, this data will be stored in the recording device and in the cloud. Once monitoring is complete, the data remains stored in the cloud and is available to physicians. During the recording, at any time, the doctor can be connected and interrogate the device in order to visualise the arrhythmias of his patient. The first studies using this device in the clinic have recently been published with very encouraging results. The device is classified in category A (Swiss government office decision attached). Previous trials with this device have shown its clinical usefulness in the intensive care unit and in daily practice. The device is actually proposed and used by many cardiologists as an alternative to the conventional Holter monitoring system. The goal of the present trial is mainly to confirm tha ability of this device to be used as a telemetry system on the ward in order to overpass the inconvenience of the actual system related to permanent cable connections with the risk of disconnexion and lost of monitoring. This trial is mainly a confirmation of that the device is a valuable option for telemetry.
The device used for this trial is the one certified by Swissmedics with UE (Union Européenne) certification
3.3 Pre-clinical evidence
The benefits of using such a type of monitoring are obvious. The patient is autonomous in his movements. The risks associated with disconnection are nonexistent. In addition, the doctor can consult the patient's data directly at any time. Finally, the data are stored in the cloud and archiving is made easier. The only risk associated with this system is an allergy to the adhesive patch. In view of the potential benefits expected from the use of this system, it is easy to understand that the study is justified. It should be kept in mind that the conventional system also has limits essentially linked to the risk of cable disconnection.
The risk linked to a bad registration of the SmartCardia system which would generate an incorrect treatment does not exist, because the clinical decision will be taken by the doctor and based only on the data provided by conventional monitoring.
Previous trials have shown the accuracy and advantages of this new wireless recorder. The system is already used in the daily practice in several countries as an alternative to conventional Holter monitoring.
3.4 Explanation for choice of comparator
The new system will be used in parallel with the conventional monitoring system. It is obvious that the conventional monitoring system should be used as the gold standard.
3.5 Risks/Benefit
There are no risks related to the use of this new device as therapeutic decision will be based only the recording of the conventional system. Benefits could be expected in the future since wireless system are preferred by the patients as demonstrated in previous trials comparing Holter monitoring and the SmartCardia device.
3.6 Justification of choice of study population
Patients after cardiac surgery are usually monitored for a few days when they are back to the ward. It is obvious that they are the cohort of choice for such monitoring since they require it anyway.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm
This is a single arm trial. The patient is his own control.
Cardiac monitoring with the wireless device "SmartCardia"
Monitoring of arrhythmia with a wireless device (SmartCardia)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac monitoring with the wireless device "SmartCardia"
Monitoring of arrhythmia with a wireless device (SmartCardia)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* refusing to participate will be excluded from the study.
* planed MRI examination
* open wound
* Severe thorax deformity making recording not possible.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Freiburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephane Cook
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Jacques Goy, MD
Role: PRINCIPAL_INVESTIGATOR
Hirslanden Cecil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Cecil
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CER 2020-0141
Identifier Type: -
Identifier Source: org_study_id